Roberto Bellini

Roberto Bellini is recorded as Chairman at Inhibikase Therapeutics, Inc. (IKT) since October 10, 2024 and Board Member at Inhibikase Therapeutics, Inc. (IKT). The newest filing on record that lists Roberto Bellini as Board Member at Inhibikase Therapeutics, Inc. (IKT) is dated April 30, 2026. Inhibikase Therapeutics, Inc. reported in an 8-K filed October 22, 2024 that Roberto Bellini was appointed Class I director of the Board, effective October 21, 2024. Inhibikase Therapeutics, Inc. reported in an 8-K filed October 22, 2024 that Roberto Bellini was appointed independent Chairperson of the Board, effective October 21, 2024. Inhibikase Therapeutics, Inc. reported in an 8-K filed October 10, 2024 that Roberto Bellini was appointed director. Equibles holds 5 filed executive changes naming Roberto Bellini; each is listed under recent activity with its source filing. Inhibikase Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Inhibikase Therapeutics, Inc. includes Mark Iwicki (CEO and Board Member), Amit Munshi (Chairman and Board Member), David McIntyre (CFO) and 4 others.